Armata Pharmaceuticals posts $54.9M Q3 2026 profit
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Armata Pharmaceuticals, Inc. (ARMP) reported third-quarter 2026 net income of $54.9 million, compared with a $26.7 million net loss a year earlier. The result was primarily driven by a $69.6 million gain from the change in fair value of its convertible loan; operating loss was $7.4 million versus $7.8 million. Grant and award revenue was $3.2 million, compared with $1.2 million, while research and development expenses were $6.8 million versus $5.8 million.
Cash and cash equivalents were $18.3 million at September 30, 2026, compared with $8.7 million at December 31, 2025; net cash used in operating activities for the first nine months was $20.0 million. Armata said preparations continued for its planned AP-SA02 Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The study was expected to initiate in the second half of 2026, with exact timing depending on FDA concurrence with the protocol. AP-SA02 has FDA Breakthrough Therapy designation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointThird-quarter net income: $54.9 million, versus a $26.7 million loss, primarily driven by the convertible-loan fair-value gain.
- Moderate pointGrant and award revenue: $3.2 million, versus $1.2 million in Q3 2025.
Negative
- None.
Filing Explained
At September 30, current liabilities included $94,309 thousand of convertible loan and $83,862 thousand of term debt.
This Form 8-K reports Armata’s third-quarter results; its September 30 balance sheet lists the convertible loan and term debt as current liabilities, whereas both appeared as non-current liabilities at December 31, 2025. It reports
The results statement separately reports
8-K Event Classification
Key Figures
Key Terms
bacteriophage therapeutics medical
Phase 3 superiority study medical
Biologics License Application (BLA) regulatory
Breakthrough Therapy designation regulatory
Qualified Infectious Disease Product (QIDP) regulatory
change in fair value financial
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ARMP report for third-quarter 2026 net income?
When is ARMP's AP-SA02 Phase 3 study expected to start?
AI-generated analysis. How Rhea-AI works. Not financial advice.
